Aro J - Search Results

1

Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors.

Mikkola A, Aro J, Rannikko S, Ruutu M; Finnprostate Group. Mikkola A, et al. Among authors: aro j. Scand J Urol Nephrol. 2009;43(4):265-70. doi: 10.1080/00365590902836500. Scand J Urol Nephrol. 2009. PMID: 19382005

2

A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer.

Mikkola AK, Aro JL, Rannikko AS, Ruutu ML; Finnprostate Group. Mikkola AK, et al. BJU Int. 2008 May;101(9):1090-5. doi: 10.1111/j.1464-410X.2007.07361.x. Epub 2007 Dec 5. BJU Int. 2008. PMID: 18070186 Clinical Trial.

3

Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate.

Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M; Finnprostate group. Mikkola A, et al. Among authors: aro j. Scand J Urol Nephrol. 2005;39(4):294-300. doi: 10.1080/00365590510031228. Scand J Urol Nephrol. 2005. PMID: 16261661 Clinical Trial.

4

Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy.

Mikkola A, Aro J, Rannikko S, Ruutu M; Finnprostate Group. Mikkola A, et al. Among authors: aro j. Prostate. 2007 Mar 1;67(4):447-55. doi: 10.1002/pros.20547. Prostate. 2007. PMID: 17219379 Clinical Trial.

5

Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group.

Mikkola AK, Aro JL, Rannikko SA, Salo JO. Mikkola AK, et al. Among authors: aro jl. Prostate. 1999 May 15;39(3):175-81. doi: 10.1002/(sici)1097-0045(19990515)39:3<175::aid-pros5>3.0.co;2-e. Prostate. 1999. PMID: 10334106

6

Family history and prostate cancer screening with prostate-specific antigen.

Mäkinen T, Tammela TL, Stenman UH, Määttänen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A. Mäkinen T, et al. Among authors: aro j. J Clin Oncol. 2002 Jun 1;20(11):2658-63. doi: 10.1200/JCO.2002.05.006. J Clin Oncol. 2002. PMID: 12039927 Clinical Trial.

7

Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.

Finne P, Auvinen A, Aro J, Juusela H, Määttänen L, Rannikko S, Hakama M, Tammela TL, Stenman UH. Finne P, et al. Among authors: aro j. Eur Urol. 2002 Jun;41(6):619-26; discussion 626-7. doi: 10.1016/s0302-2838(02)00179-3. Eur Urol. 2002. PMID: 12074779 Clinical Trial.

8

Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen.

Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A. Mäkinen T, et al. Among authors: aro j. Clin Cancer Res. 2003 Jul;9(7):2435-9. Clin Cancer Res. 2003. PMID: 12855615

9

Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial.

Auvinen A, Määttänen L, Finne P, Stenman UH, Aro J, Juusela H, Rannikko S, Tammela TL, Hakama M. Auvinen A, et al. Among authors: aro j. Int J Cancer. 2004 Oct 10;111(6):940-3. doi: 10.1002/ijc.20352. Int J Cancer. 2004. PMID: 15300807 Clinical Trial.

10

Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007.

Pogodin-Hannolainen D, Juusela H, Tammela TL, Ruutu M, Aro J, Määttänen L, Auvinen A. Pogodin-Hannolainen D, et al. Among authors: aro j. J Med Screen. 2011;18(1):46-9. doi: 10.1258/jms.2010.010090. J Med Screen. 2011. PMID: 21536817

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters